Used in research to study the role of GPR40 (FFAR1) receptors in insulin secretion and glucose homeostasis. Helps investigate potential therapeutic strategies for type 2 diabetes by modulating receptor activity. Enables evaluation of beta-cell function and insulin release in response to fatty acid signaling. Employed in preclinical studies to assess efficacy, selectivity, and metabolic effects of FFAR1-targeting compounds. Supports drug discovery efforts aimed at developing new antidiabetic agents with improved glucose control and reduced hypoglycemia risk.